Pfizer and Anumana Ink Multi-Year AI Electrocardiogram Algorithm Deal
Related Articles
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…May 23, 2022
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 Certification
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 CertificationCAMBRIDGE, Mass. – May 21, 2024 – Anumana, a leading AI-driven health technology company and portfolio company of nference, announced today…May 21, 2024
Anumana Advances AI-Driven Cardiovascular Science with Late-Breaking Heart Failure Study and Multiple Abstracts at AHA 2025
Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in AI-powered cardiovascular diagnostics, today announced…November 20, 2025
How Doctors Use AI to Help Diagnose Patients
Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially…February 28, 2023